Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Yu Tuan Wu"'
Autor:
Bilal Arshad, Saima Khan, Vishnu Prasad Adhikari, Yu Tuan Wu, Hao Ran Chen, He Wu, Ling Quan Kong
Publikováno v:
International Journal of Endorsing Health Science Research, Vol 4, Iss 3, Pp 1-11 (2016)
World widely, Breast cancer is the most common type of cancer amongst women. External and internal factors both are responsible for beginning, advancement and development of breast cancer and from many studies it is well known that environmental elem
Externí odkaz:
https://doaj.org/article/8627f44f81864bee8a3411d16495b29c
Autor:
Xin Li, Zi-li Liu, Yu-tuan Wu, He Wu, Wei Dai, Bilal Arshad, Zhou Xu, Hao Li, Kai-nan Wu, Ling-quan Kong
Publikováno v:
Lipids in Health and Disease, Vol 17, Iss 1, Pp 1-6 (2018)
Abstract Background The lipid profile status among breast cancer patients at initial diagnosis and during chemotherapy remain controversial. The aim of this study is to study the status of lipid and lipoprotein in female breast cancer patients at ini
Externí odkaz:
https://doaj.org/article/78a63440bfcc446e8ec8e4e9ce0043a8
Autor:
Hao-ran Chen, Yu-tuan Wu, Qiu-bo Yu, Ya-ying Yang, Yu-xian Wei, Hong-yuan Li, Kai-nan Wu, Ling-quan Kong
Publikováno v:
World Journal of Surgical Oncology, Vol 15, Iss 1, Pp 1-5 (2017)
Abstract Background A few retrospective studies have indicated that neoadjuvant chemotherapy (NAC) in breast cancer may change biomarker profiles of the primary tumor. Little is known about the status of HER-2 gene of the synchronous nodal metastases
Externí odkaz:
https://doaj.org/article/3117419aa7064c519af2c9dcee9141b0
Autor:
Yu-Tuan Wu, Xin Li, Zi-Li Liu, Zhou Xu, Wei Dai, Ke Zhang, Jiu-Song Wu, Bilal Arshad, Kai-Nan Wu, Ling-Quan Kong
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0179680 (2017)
Antiviral drugs have been recommended as prophylaxis for the reactivation of hepatitis B virus (HBV) infection in cancer patients undergoing chemotherapy. However, screening and antiviral prophylaxis for lung cancer remain controversial because of in
Externí odkaz:
https://doaj.org/article/5c9ef36929f74d25a1e389b0fbd21265
Autor:
Zhou Xu, Yu-Tuan Wu, Xin Li, He Wu, Hao-Ran Chen, Yan-Ling Shi, Bilal Arshad, Hong-Yuan Li, Kai-Nan Wu, Ling-Quan Kong
Publikováno v:
Chinese Medical Journal, Vol 130, Iss 16, Pp 1995-1996 (2017)
Externí odkaz:
https://doaj.org/article/d97cfbd61f65424785eea1f9571c67af
Publikováno v:
Chinese Medical Journal, Vol 130, Iss 16, Pp 2015-2016 (2017)
Externí odkaz:
https://doaj.org/article/4a065c08fb084bd98127681f2ecf60c3
Autor:
Xin Li, Zhou Xu, Liang Ran, Chunxia Zhao, Kai-nan Wu, Hao-Ran Chen, Yu-tuan Wu, He Wu, Hao Li, Yan-Ling Shi, Bilal Arshad, Qingqing Luo, Lingquan Kong, Hongyuan Li
Publikováno v:
Journal of Cancer
Metabolic syndrome has been previously identified as a risk factor for breast cancer and is increasingly a public health concern. This study aims to investigate the prevalence of metabolic syndrome and its components among primary breast cancer and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71724973f2b321605de503b122235953
https://doi.org/10.7150/jca.22968
https://doi.org/10.7150/jca.22968
Autor:
Zhou Xu, Jiu-song Wu, Kai-nan Wu, Bilal Arshad, Ke Zhang, Yu-tuan Wu, Xin Li, Lingquan Kong, Hao Li, He Wu, Ying-Cun Li, Zhong-Liang Wang
Publikováno v:
Journal of Cancer
Objectives: To investigate the effect of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy (NAC) for HER2-positive breast cancer in terms of pCR and cardiotoxicity. Methods: We systematically searched Pubmed, Embase,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b2746c42fe2d486d36150d66bf546c8
https://doi.org/10.7150/jca.24701
https://doi.org/10.7150/jca.24701
Autor:
Yu-tuan Wu, Wei Dai, He Wu, Qingqing Luo, Lingquan Kong, Kai-nan Wu, Xin Li, Chunxia Zhao, Jianbo Huang
Publikováno v:
Medical Hypotheses. 102:4-7
Neoadjuvant chemotherapy remains an inseparable part of systemic therapy for hormone receptor positive (HR+) advanced breast cancer. However, efficacy of neoadjuvant chemotherapy in this subtype of patients is inferior to its hormone receptor negativ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28bca8ee677c5bb501adc934870d871
https://doi.org/10.1016/j.mehy.2017.03.003
https://doi.org/10.1016/j.mehy.2017.03.003
Autor:
Linjie Lu, Jianbo Huang, Lingquan Kong, He Wu, Vishnu Prasad Adhikari, Yuxian Wei, Chunxia Zhao, Qingqing Luo, Wei Dai, Kai-nan Wu, Yu-tuan Wu, Xin Li
Publikováno v:
Oncotarget
// He Wu 1 , Chunxia Zhao 1 , Vishnu Prasad Adhikari 1 , Linjie Lu 2 , Jianbo Huang 1 , Yuxian Wei 1 , Qingqing Luo 1 , Wei Dai 1 , Yutuan Wu 1 , Xin Li 1 , Kainan Wu 1 , Ling-Quan Kong 1 1 Department of Endocrine and Breast Surgery, The First Affili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db311ba3ef3fa27fbceb05cabbeb90b4
http://europepmc.org/articles/PMC5392318
http://europepmc.org/articles/PMC5392318